Tiziana Life Sciences (TLSA) announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access for patients with non-active secondary progressive multiple sclerosis who do not qualify for the ongoing Phase 2a study. To date, 14 patients have now been enrolled in the expanded access program. The first 10 patients have all shown either an improvement or stability of disease within 6 months of starting treatment. The na-SPMS expanded access program allows patients who do not meet the inclusion criteria for the ongoing Phase 2a clinical trial to receive treatment with Tiziana’s investigational therapy, intranasal foralumab.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Highlights Foralumab’s Potential in Alzheimer’s Treatment
- Tiziana announces TV interview with AD patient dosed with foralumab
- Tiziana Life Sciences Faces Nasdaq Compliance Challenge
- Tiziana Life Sciences Reports Breakthrough in Spinal Cord Injury Treatment
- Tiziana will not engage in capital raising activities for ‘immediate future’